News Report · Endocrinology

FDA Approves Langlara for Diabetes: Interchangeable Biosimilar to Lantus

June 11, 2026

Clinical Perspective

Langlara will be utilized by healthcare providers for patients with Type 1 and Type 2 diabetes who require insulin therapy. The approval of this interchangeable biosimilar provides an opportunity to improve glycemic control at potentially lower costs. How will this impact patient adherence to diabetes management plans?

Dr. Amit Desai · Endocrinology

Langlara (insulin glargine-aldy) has been approved by the FDA as an interchangeable biosimilar to Lantus (insulin glargine) for the management of Type 1 and Type 2 diabetes. This approval, announced on April 29, 2026, aims to enhance patient access to insulin therapy in the United States ^[1].

Clinical Context

Diabetes is a chronic condition characterized by high blood sugar levels due to insulin deficiency or resistance. It affects over 38 million people in the U.S., with approximately 8.4 million relying on insulin therapy to manage their condition. Current standard treatments include long-acting insulins like Lantus, which help maintain blood glucose levels throughout the day. However, the high cost of insulin can be a barrier for many patients. The approval of Langlara as a biosimilar to Lantus is expected to provide a more affordable option for patients, potentially improving adherence to treatment and overall glycemic control.

Key Findings

The FDA approved Langlara (insulin glargine-aldy) as an interchangeable biosimilar to Lantus (insulin glargine) for the treatment of Type 1 and Type 2 diabetes ^[1].
This approval is part of the FDA's ongoing efforts to increase access to safe and effective diabetes treatments, particularly biosimilars that can offer lower-cost alternatives to existing therapies.
The introduction of Langlara is expected to enhance competition in the insulin market, potentially leading to lower prices for patients and improved access to essential diabetes management tools.
Insulin glargine-aldy is administered via subcutaneous injection, similar to Lantus, and is designed to provide a consistent release of insulin to help control blood sugar levels throughout the day.
The approval of Langlara follows the FDA's previous approvals of other biosimilar insulins, reflecting a growing trend towards expanding treatment options for diabetes patients in the U.S.
Clinicians should consult the prescribing information for Langlara for detailed dosing guidance and administration instructions.

Safety & Tolerability

Hypoglycemia reported with Langlara — monitor during treatment ^[1].
Injection site reactions reported — exact frequency not available in public source summary ^[1].
Weight gain reported ^[1].
Allergic reactions reported ^[1].
Changes in renal function — monitor renal function during treatment ^[1].
Complete adverse event profile available in the full prescribing information for Langlara (insulin glargine-aldy) ^[1].

Study Design

Langlara was evaluated through a series of clinical studies that demonstrated its biosimilarity to Lantus, ensuring no clinically meaningful differences in safety or efficacy. The studies included diverse populations with both Type 1 and Type 2 diabetes, focusing on glycemic control as the primary endpoint. The FDA's approval process for Langlara included rigorous assessments to confirm its therapeutic equivalence to the reference product, Lantus.

FAQ

What is Langlara approved for?

Langlara (insulin glargine-aldy) is approved for the treatment of Type 1 and Type 2 diabetes as an interchangeable biosimilar to Lantus (insulin glargine) as of April 29, 2026.

How does Langlara work?

Langlara works by providing a long-acting insulin that helps control blood sugar levels in patients with diabetes, mimicking the action of natural insulin produced by the pancreas.

What is the recommended dose of Langlara?

Full dosing guidance is available in the prescribing information for Langlara (insulin glargine-aldy).

What are the most common side effects of Langlara?

Common side effects include hypoglycemia, injection site reactions, weight gain, allergic reactions, and changes in renal function.

How does Langlara compare to Lantus?

Langlara is an interchangeable biosimilar to Lantus, designed to provide similar safety and efficacy in managing blood sugar levels in patients with diabetes.

Who qualifies for Langlara treatment?

Langlara is indicated for adults and pediatric patients with Type 1 and Type 2 diabetes who require insulin therapy.

FDA Approves Langlara for Diabetes: Interchangeable Biosimilar to Lantus

FDA Approves Langlara for Diabetes: Interchangeable Biosimilar to Lantus

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly drug updates for Endocrinology in your inbox.

Related Drug Updates

FDA Approves Semaglutide for Cardiovascular Risk: 20% MACE Reduction in SELECT Trial

FDA Approves Tirzepatide for Chronic Weight Management: 18% Weight Reduction in SURMOUNT-1 Trial

FDA Approves Jubbonti as Interchangeable Biosimilar to Prolia for Osteoporosis

Verified HCP Portal